Delhi High Court Intervenes to Revive Rare Disease Crowdfunding Platform

In a landmark move to address India’s rare disease treatment crisis, the Delhi High Court has ordered the formation of a four-member expert panel to oversee and revamp the national crowdfunding platform hosted by the Ministry of Health and Family Welfare. The platform, designed to support patients with life-threatening rare diseases, has so far failed to mobilize adequate public and corporate donations.

Judicial Trigger: A Mother's Plea for Life-Saving Treatment

The court’s intervention was prompted by a petition filed by the mother of an infant diagnosed with Spinal Muscular Atrophy (SMA)—a genetic neuromuscular disorder that causes progressive muscle wasting and respiratory failure. The child requires Zolgensma, a one-time gene therapy injection costing ₹17.5 crore, available only overseas. Despite being registered on the government’s crowdfunding portal, the family had received negligible financial support.

Justice Sachin Datta, presiding over the case, expressed concern over the platform’s underperformance. Of the 3,981 patients registered, only ₹3.91 lakh had been raised in total—highlighting a systemic failure in public outreach and donor engagement.

Understanding Rare Diseases and Their Costs

Rare diseases, also known as orphan diseases, affect a small percentage of the population but often require high-cost, precision therapies such as gene replacement, enzyme infusions, or biologics. These treatments are typically not covered under standard insurance or public health schemes due to their exorbitant costs and limited availability.

India’s National Policy for Rare Diseases (NPRD) 2021 aims to address this gap by enabling innovative funding mechanisms, including public donations and Corporate Social Responsibility (CSR) contributions.

Panel Composition and Mandate

The newly constituted committee includes:

• A Joint Secretary from the Department of Public Enterprises, Ministry of Finance
• Representatives from the Ministry of Health and Family Welfare
• Experts in CSR strategy and public health policy

The mandate:

• Boost CSR and public donations through strategic outreach
• Ensure transparency in fund allocation and patient prioritization
• Enhance platform credibility to attract sustained donor engagement

Crowdfunding Platform: How Donors Can Help

The official portal—https://rarediseases.nhp.gov.in—allows individuals and companies to:

• View verified patient profiles with medical documentation
• Donate securely via UPI, net banking, or card
• Receive tax benefits under Section 80G (subject to eligibility)
• Contribute under CSR mandates with official acknowledgment

Why This Matters

India faces a growing burden of rare diseases, with thousands of families unable to afford life-saving therapies. While government schemes offer partial support, crowdfunding can bridge the financial gap—but only if platforms are well-managed, transparent, and widely promoted.

The Delhi High Court’s directive is a critical step toward systemic reform, ensuring that India’s rare disease patients are not left behind due to funding failures.

Hormone Harmony: Why Women Are Choosing Plant Oils Over Synthetic Pills

- Satya Tiwari, MD & CEO, Voll Sante

Across the world, more women are exploring plant-based alternatives to synthetic hormone pills to support hormonal balance. This shift reflects growing awareness about side effects
linked with conventional hormone therapies and a preference for natural, gentler approaches that align with broader lifestyle and wellness choices.

Hormone replacement therapy (HRT) has long been prescribed to manage symptoms of menopause such as hot flashes, night sweats, and mood changes. While it remains an effective option for many, studies like the Women’s Health Initiative (WHI) found that long-term use of combined estrogen and progestin therapy could increase the risk of cardiovascular disease, blood clots, and breast cancer in certain groups of women. These findings led many to look for safer or more individualized options.

Plant-based alternatives often include bioidentical hormones derived from plant precursors, botanical extracts, and seed oils rich in essential fatty acids. Compounds like phytoestrogens — found in soy, flaxseed, and red clover — can mimic estrogen in the body and may offer mild relief from symptoms of estrogen decline. A 2016 meta-analysis in JAMA reviewed 62 trials involving more than 6,600 women and found that phytoestrogen supplements led to modest reductions in hot flashes and improvements in vaginal dryness, although results varied widely between studies. Researchers also noted that many trials were small and short-term, so the evidence is not yet conclusive.

Plant oils such as flaxseed, evening primrose, and borage oil are also used for their omega-3 and omega-6 fatty acids, which play a role in hormone production and inflammation regulation. Though popular in integrative medicine, scientific data linking these oils directly to hormone balance remains limited. Some small studies suggest that regular intake may improve premenstrual or menopausal symptoms, but larger, well-controlled research is still needed.

The use of essential oils and aromatic plant extracts for hormonal support is another growing area of interest. Preliminary studies indicate that certain compounds found in lavender, clary sage, and fennel oils may influence stress or estrogen-related pathways. However, most of this research is early-stage, and experts caution that essential oils should be used carefully, especially for internal use or during medical treatments.

One reason for the rise in plant-based hormone support is the growing demand for individualized care. Many women report that standard hormone doses feel too strong or cause side effects such as bloating, headaches, or mood changes. In response, some practitioners offer compounded bioidentical hormones — customized formulations designed to match a woman’s specific hormone profile. These are often derived from plant sources but are still chemically processed to resemble natural hormones. The U.S. Food and Drug Administration (FDA) notes that while these hormones are sometimes marketed as “natural” or “safer,” there is no strong evidence that they are risk-free or more effective than approved hormone therapies.

A 2023 review by the Endocrine Society reiterated that compounded bioidentical hormones lack consistent quality control and standardized dosing, which can lead to unpredictable outcomes. The organization recommends that patients use approved hormone therapies when available and discuss all options with qualified healthcare providers before switching to plant-based or compounded formulations.

At the same time, the shift toward natural solutions is supported by broader lifestyle and wellness trends. Women are increasingly approaching hormonal health as part of a larger ecosystem that includes nutrition, sleep, stress management, and gut health. Within this framework, plant oils and botanical compounds are viewed not as replacements for medicine but as complementary tools that support balance and overall well-being.

Surveys suggest that around 40 to 50 percent of women experiencing menopause now use some form of complementary or alternative therapy, including plant-based remedies. The reasons range from fear of side effects to a desire for holistic, preventive care. However, medical experts continue to emphasize that “natural” does not automatically mean “safe.” Some plant-derived compounds can interact with medications or be unsuitable for women with hormone-sensitive conditions.

For those considering a transition away from synthetic pills, experts recommend a gradual, supervised approach. Hormone testing, symptom tracking, and medical consultation can help ensure that any new regimen—whether based on plant oils, phytoestrogens, or lower-dose bioidentical hormones—is safe and effective.

The move toward plant-based hormonal support reflects a wider shift in health choices: women seeking more control, more information, and more natural interventions. While scientific evidence continues to evolve, the conversation around hormone balance is becoming broader and more nuanced, bridging traditional medicine with modern integrative approaches.

Cough Syrup Horror: Banned Chemical Used, Pharma Firm Under Probe

The Special Investigation Team (SIT) probing the Coldrif cough syrup tragedy in Madhya Pradesh has confirmed that industrial-grade diethylene glycol—a toxic chemical used in brake fluids and antifreeze—was present in the syrup that led to the deaths of 23 children, including 20 in Chhindwara district.

Key Findings from the SIT Investigation:

• Source of Contamination: The chemical was traced to Sresan Pharmaceuticals, owned by Ranganathan Govindan in Tamil Nadu. He allegedly procured banned industrial-grade diethylene glycol for production.
• Supply Chain Mapping: Investigators are now examining the entire supply chain—from raw material sourcing to distribution—to determine how long the chemical had been used and who else may be complicit.
• Accountability Focus: Authorities aim to fix responsibility at every stage, including suppliers, intermediaries, and production oversight. Govindan initially claimed ignorance, saying production was delegated.

Source: Times of India | The Indian Express [October 11, 2025] 

The Coldrif cough syrup tragedy was first reported by several national and regional outlets, but among the earliest and most locally grounded coverage came from India Today, on October 7, by reporter Ravish Pal Singh, based in Bhopal. The report highlighted the rising death toll in Chhindwara and Betul districts, naming victims and linking the deaths to Coldrif syrup containing toxic substances.

Regulatory Implications

This case has reignited calls for tighter pharmaceutical oversight and raw material traceability. It echoes past tragedies involving toxic syrups and highlights the urgent need for reform in drug manufacturing protocols.

Understanding Urban Fatigue Through Nutrition

— Satya Tiwari, MD & CEO- Voll Sante 

Urban tiredness, foggy thinking and the slow burn of burnout are so common now that many assume they’re just part of city life: long commutes, late nights, screens and stress. That explanation explains some of it, but it’s incomplete. A growing body of research points to a second, less visible cause - widespread microscopic nutritional shortfalls and impaired cellular repair that quietly erode energy generation, mental clarity and resilience. When cells can’t produce clean energy, when antioxidant systems are weak, and when key cofactors for brain and muscle function are missing, people feel tired even after “enough” rest.

Satya Tiwari 

National surveys confirm that anaemia remains high across the population. Studies also show that vitamin D insufficiency affects a large share of urban Indians, while deficiencies in vitamin B12 and iron are frequently reported among adults who complain of tiredness or poor concentration. Magnesium deficiency is an under-recognized contributor to urban fatigue. Low magnesium - common where diets are low in whole grains, nuts, seeds and leafy greens, and where stress and processed foods are prevalent - is linked to muscle weakness, poor sleep, anxiety and the brain fog people describe.

These nutrients are not minor extras. Iron carries oxygen and powers mitochondrial enzymes, B-vitamins act as essential cofactors for energy cycles and neurotransmitter synthesis, vitamin D influences muscle strength and mood, while magnesium supports mitochondrial enzymes and is also required for vitamin D metabolism. When levels of these nutrients run low, cells produce energy less efficiently and generate more oxidative stress, which further damages mitochondria and slows repair.

Over time, this biochemistry translates into the symptoms many city dwellers report: constant fatigue, foggy focus, low resilience and even reduced mobility. Screening and addressing iron, B12, vitamin D and magnesium together can therefore be more effective in improving outcomes for people with persistent tiredness.

Evidence also shows that correcting these shortfalls can make a real difference. Iron repletion reduces fatigue even before anaemia becomes severe. Vitamin B12 replacement restores neurological function when levels are low, and vitamin D correction improves muscle performance and mood. Clinical studies suggest mitochondrial cofactors such as Coenzyme Q10 may help people with persistent fatigue, especially where there are signs of oxidative stress. What matters most is a measured approach: testing for deficiencies first, then correcting with targeted, bioavailable nutrients rather than relying on one-size-fits-all multivitamins.

Absorption is a critical piece often overlooked. Urban diets heavy in processed foods, irregular meal timing and digestive issues reduce how much of a nutrient the body actually uses. Choosing better-absorbed forms - such as chelated minerals, active B-vitamin forms, or pairing iron-rich foods with vitamin C - improves results. Equally, everyday habits like spacing tea and coffee away from meals, including protein at each sitting, and using fermented foods to support gut health help the body extract more from what we eat.

Lifestyle changes complement nutrition in repairing energy systems. Consistent sleep, daily movement like brisk walking, and short stress-control practices reduce background metabolic strain and allow mitochondria to recover. Even small changes, when combined with targeted nutrient correction, can shift energy and clarity noticeably.

On a larger scale, workplaces and communities can make an impact by offering simple screenings, creating awareness about common deficiencies, and providing access to fortified or functional foods designed for better absorption. These steps are practical for city life and can improve both wellbeing and productivity.

Urban fatigue is not just about being busy. It is also about cells running below capacity because they lack the tools to make clean energy and repair themselves. The science is clear: checking and correcting iron, vitamin B12 and vitamin D levels, ensuring nutrients are absorbed efficiently, and supporting mitochondrial health can reduce the exhaustion that has come to define urban living. For anyone feeling persistently tired despite rest, the first step is not just more coffee or another weekend off - it is a simple blood test and a plan to rebuild energy from the cellular level up.

Esports Athlete Health Programs: Physical Conditioning for Professional Gamers

You wouldn't think sitting at a computer for 12 hours a day would require athletic 44 conditioning — but you'd be wrong. The esports industry has learned this lesson the hard way. Players who seemed invincible at 18 were burning out by 22, their careers cut short by injuries that traditional sports medicine barely understood. And betting platforms like 1xbet? They've started paying attention to these health metrics because they directly impact player performance and market predictions.

I've watched this transformation happen in real-time. What started as a few stretching exercises between matches has evolved into comprehensive health programs that rival those of traditional sports teams. The numbers don't lie — teams with structured health programs consistently outperform those without them.

The physical toll of professional gaming is more severe than most people realize. We're talking about repetitive strain injuries that can end careers, postural problems that cause chronic pain, and eye strain that affects reaction times. But here's what's interesting: the teams that addressed these issues first gained a competitive advantage that's still paying dividends today.

Systematic Health Monitoring and Injury Prevention

Modern esports organizations don't wait for problems to develop — they prevent them. Esports health monitoring systems show how teams track everything from wrist flexibility to cardiovascular health.

The most effective programs I've seen address multiple areas simultaneously:

• Biomechanical assessments that identify potential injury risks before they become problems
• Targeted strength training programs that counteract the effects of prolonged sitting
• Eye care protocols that go beyond basic vision correction to include reaction time optimization
• Nutritional planning that supports sustained cognitive performance during tournaments
• Sleep pattern analysis and optimization for irregular competition schedules

Take Team Liquid's approach. When they implemented their health program in 2019, they weren't just trying to prevent injuries — they were looking for a competitive edge. The results? A 40% reduction in player injuries and an 8% improvement in average reaction times. That might not sound like much, but in esports, milliseconds matter.

But here's where it gets interesting. The teams that initially resisted these programs — thinking they were unnecessary overhead — found themselves at a disadvantage. Players started requesting trades to teams with better health support. The market spoke, and organizations listened.

Physical Training Adapted for Gaming Performance

Traditional athletic training doesn't work for esports athletes. You can't just throw them into a standard gym routine and expect results. Gaming-specific fitness programs reveal how specialized exercises improve gaming performance while preventing common injuries.

The training programs that work best focus on counteracting the negative effects of gaming posture. I've seen players transform their performance through targeted exercises that strengthen core muscles, improve hand-eye coordination, and increase cardiovascular endurance. It's not about building bulk — it's about building the specific type of fitness that gaming demands.

Gen.G's facility includes a full gymnasium, but it's not what you'd expect. Their players spend two hours daily on conditioning that's specifically designed for gaming. Yoga sessions improve flexibility and reduce tension. Strength training focuses on postural support. Cardio work increases blood flow to the brain, supporting the sustained concentration needed during long matches.

The results speak for themselves. Gen.G's League of Legends team showed a 15% improvement in late-game performance metrics after implementing their program. That's not coincidence — that's the direct result of players maintaining physical conditioning that supports their mental performance.

Mental Health Integration and Cognitive Performance

Here's something most people don't realize: physical fitness directly impacts mental performance in gaming. The teams that understand this connection have a significant advantage over those that don't.

Mental health support in esports addresses unique challenges. Players face intense scrutiny from fans, pressure to perform consistently, and the psychological toll of public competition. Physical exercise programs help manage stress and anxiety while improving mood and cognitive function. It's a virtuous cycle — better physical health leads to better mental health, which leads to better performance.

Cloud9's integrated approach combines physical fitness with mental health support in ways that make sense for their players. Group fitness activities build team cohesion while maintaining individual health goals. The program includes meditation sessions, stress management workshops, and one-on-one counseling when needed. They've found that players who maintain higher fitness levels demonstrate better decision-making under pressure and greater consistency across tournament play.

The data shows clear connections between physical fitness and competitive performance. Players who maintain higher fitness levels show improved reaction times, better decision-making under pressure, and greater consistency across tournament play. These metrics have become increasingly important for performance analysis and strategic planning.

Recovery protocols have evolved to match the demanding schedules of professional esports. Teams now implement structured rest periods, active recovery sessions, and sleep optimization programs. The goal isn't just maintaining peak performance — it's preventing burnout and physical deterioration that can end careers prematurely.

Some organizations have invested heavily in specialized recovery equipment. Massage therapy, cryotherapy chambers, and compression therapy systems help players recover from the physical stress of intense gaming sessions while maintaining their competitive edge. It sounds excessive until you see the results.

Recovery Technology Centers: Transforming Athletic Performance and Career Longevity

I've spent considerable time observing how professional sports recovery has evolved, and frankly, it's been remarkable to witness. What we're seeing now in recovery technology centers would've been pure fantasy when I first started following sports medicine. These facilities don't just offer basic ice baths anymore — they're running cryotherapy chambers at -129°C, using pneumatic compression systems that can mimic your body's natural circulation patterns, and monitoring every single biomarker imaginable.

Here's what strikes me most: the predictability factor. Athletes using these systems create more consistent performance patterns, which directly impacts how analysts and enthusiasts approach sports betting through platforms like 1xbet mobile download. When you can predict player availability and performance consistency with greater accuracy, it changes the entire dynamic of sports analysis.. 

The Science Behind Cryotherapy and Compression Recovery

 Let me break down what's actually happening in these recovery centers, because the science is genuinely fascinating. Cryotherapy research studies show that controlled cold exposure — we're talking -129°C to -140°C for 2-4 minutes — triggers a cascade of physiological responses that traditional ice baths simply can't match.

What you'll find in a modern recovery facility:

• Whole-body cryotherapy chambers with nitrogen cooling systems that maintain precise temperatures
• Pneumatic compression systems applying graduated pressure from 20-60 mmHg in controlled sequences
• Infrared therapy beds that penetrate tissue up to 4cm deep without surface heating
• Hyperbaric oxygen chambers increasing dissolved oxygen in blood plasma by 1200%
• Real-time monitoring systems tracking inflammation markers, heart rate variability, and tissue response

The numbers don't lie. Athletes using comprehensive recovery protocols experience 40% fewer soft tissue injuries compared to traditional methods. I've seen NBA data showing players miss an average of 12 fewer games per season when they're using cryotherapy consistently. But here's what's really interesting — it's not just about injury prevention anymore.

Compression Systems and Performance Monitoring

Pneumatic compression therapy has moved way beyond those basic massage boots you might remember. Modern systems use compression therapy athletic recovery to create precisely controlled pressure waves that push metabolic waste through your lymphatic system. These aren't one-size-fits-all treatments either — they're customized based on your body composition, training load, and recovery needs.

The monitoring aspect is where things get really sophisticated. Each session generates data about tissue response, blood flow changes, and recovery markers. Teams can now predict when an athlete will return to peak performance with 85% accuracy — that's up from about 60% just five years ago.

Heart rate variability measurements, taken first thing in the morning, provide coaches with daily readiness scores. If a player shows poor recovery metrics, they might get modified training loads or additional recovery treatments. It's become incredibly precise.

The Business Impact of Predictable Recovery

Professional teams aren't investing in these recovery centers just because they look impressive — the ROI is measurable and substantial. The Lakers spent €2.3 million on their recovery facility in 2019 and reported a 30% reduction in injury-related salary costs within two years. That's real money we're talking about.

The Warriors' recovery center processes over 200 athlete sessions weekly with four cryotherapy chambers and eight compression systems. But what's really changed the game is how this predictability extends beyond professional teams.

Sports medicine clinics now offer the same recovery protocols that professional teams use. College and amateur athletes can access these treatments, which creates more standardized performance patterns across different competition levels. From a betting perspective, this standardization makes performance analysis more reliable.

Each cryotherapy session generates temperature profiles, skin temperature changes, and physiological responses. Compression therapy systems track pressure applications, duration, and tissue response patterns. This data helps create personalized recovery protocols that adapt to individual needs — and I mean truly personalized, not just generic programs.

The psychological component can't be overlooked either. Athletes report feeling more confident about their physical readiness when they have access to advanced recovery technology. This confidence translates into better performance and reduced anxiety about injury risks. It's a feedback loop that reinforces itself.

What we're seeing is a fundamental shift toward data-driven athlete care. Teams make decisions based on objective measurements rather than gut feelings or traditional assessments. When an athlete's recovery metrics show full restoration, coaches can confidently increase training intensity or playing time without second-guessing themselves.

Prevention has become more cost-effective than treatment, especially for professional athletes whose salaries depend on availability. By identifying early signs of overuse or incomplete recovery, these systems help athletes avoid injuries that could sideline them for weeks or months.

Looking ahead, I expect we'll see artificial intelligence integrated into recovery protocols to predict optimal treatments for individual athletes. Machine learning algorithms will analyze thousands of recovery sessions to identify patterns that human observers might miss.

The financial implications are significant for everyone involved. Teams that invest in comprehensive recovery technology see measurable returns through reduced injury costs and improved player availability. For professional sports, where a single injury can cost millions in lost revenue and replacement player salaries, these recovery centers represent smart business investments that pay dividends season after season.

Recovery technology centers have fundamentally changed how professional athletes approach training and competition. By providing predictable, measurable recovery outcomes, these facilities create more reliable performance patterns that benefit athletes, teams, and sports analysis alike.

Limitless Therapy & Wellness is Redefining What Physical Therapy in Greenville, SC Should Look Like

The healthcare system often leaves patients frustrated: long waitlists, confusing payment rules, and care plans that feel more generic than personal. Limitless Therapy & Wellness, a leading provider of physical therapy in Greenville was built to challenge that model and deliver something better.

At the heart of Limitless is Dr. Jordan Floyd, who combined years of experience in professional sports and outpatient care to design a clinic where patients actually feel cared for. His vision was simple but powerful: direct access to quality care, transparent pricing, and individualized treatment. No barriers, no middlemen, no wasted time.

This approach has made Limitless one of the most trusted names in the Greenville community. With 300+ five-star reviews across Google, Yelp, and Facebook, patients repeatedly emphasize the consistency of care, the attention to detail, and the long-lasting results. From everyday athletes looking to stay active and mobile, to stay-at-home parents balancing health with family life, Limitless delivers solutions that adapt to real-world needs.

What makes the clinic stand out is more than just expertise — it’s the commitment to treating people as partners in their recovery. Each session is designed not only to reduce pain but also to equip patients with the tools to stay active and independent.

In a city with many healthcare options, Limitless Therapy & Wellness has become a top choice for physical therapy in Greenville because it delivers results that matter. It’s proof that when care is designed around patients, the community takes notice.

Mixed Reality Saves Mobility: Bengaluru Surgeons Rewire Hope in Rare Spine-Brain Procedure

In a case that truly showcased the technological advancements achieved by Bangalore, India in the field of Neuroscience, Niyati (name changed), a 37-year-old young IT Professional from Bengaluru working at US decided to head home for a complex surgery at the junction on base of the skull and upper part of the spine. She was Quadriparetic, which made her bedridden with complete loss of the ability to walk, use her hands or even control urination. When she consulted the neurosurgical center at the US, she was informed that due to the complexity of the surgery she might end up permanently weak in all four limbs and might even need ventilator support for breathing. This had shattered her self-confidence and increased the burden on her family.

6 months before, she noticed the first symptoms, which started with numbness in the limbs and muscle weakness that eventually progressed to quadriparesis. She was diagnosed with Atlantoaxial Dislocation after she moved to India for her treatment, which is basically loss of stability between the two topmost bones of the vertebrae. This condition usually arises due to a congenital deformity, which leads to the compression of the spinal cord that in turn results in neurological problems - culminating into quadriparesis in her case.

Since both bones are placed in a very complicated position, extremely close to the brain stem, it was imperative to gain a clear idea of where and how to operate. The treatment of such complex disorders requires expertise and technology. Technology played a very significant role at this juncture by providing the doctors with clear images that enabled them to plan the surgery in detail. In one-of-its kind situation, the surgical team at Aster Whitfield Hospital utilized Mixed Reality (Augmented Reality + Virtual Reality) to precisely measure the severity of the compression of the brain stem and spinal cord junction, identified bony compressive elements and to locate the vertebral artery in relation to the bones, understand the anatomy of dislocated bone and also rehearse the surgery first.

Mixed Reality (MR), which blends Augmented and Virtual Reality, provides 3D, immersive visualization of the spine with much greater depth perception and spatial awareness than traditional 2D imaging. It enables physicians to examine complex spinal anatomy, plan operations with precision, and diagnose deformities, fractures, and tumors more accurately. Going beyond assisting surgeons, MR also assists patients and families in understanding complicated conditions and procedures better, decreasing fear and enabling informed decision-making.

“Mixed Reality (Augmented Reality + Virtual Reality) greatly helped us to identify the exact position of the arteries to operate on. It also enabled us to anticipate any problems or complications we might face on the table and to prepare for it better.”, said Dr. Ramachandran G, Consultant – Spine & Deformity Surgeon, Aster Whitefield Hospital, Bengaluru. “It provided clear images of the spinal structures that improved our precision and led to a successful outcome.”

The surgery went on for 5 hours which included repositioning of the displaced bones carefully to achieve normal alignment and stability of the spine along with releasing the contracted tissues surrounding the brainstem and vertebral artery that had compressed or tightened. This allowed for better circulation and a reduction in the risk of neurological disorders as well. However, the procedure presented several challenges. Mid-operation bleeding was meticulously managed by the doctors, while neural damage was mitigated through intraoperative neuromonitoring. The surgical team headed by Prof. Dr Satish Rudrappa, Group Director – Aster International Institute of Neurosciences and Spine Care and Dr Ramachandran Govindasamy, Consultant – Spine & Deformity Surgeon at Aster Whitefield Hospital.

“The surgical screws were fed in to intraoperative navigation and the screw trajectories were guided by us to achieve precision. In addition to helping us, Mixed Reality (Augmented Reality + Virtual Reality) assisted the patient and her family to understand the condition as well. It made understanding the problem and surgical procedure easier through holographic imaging which made them trust the process and agree to the surgery faster. This innovative approach allowed for precise navigation and execution of the surgery, leading to a successful outcome.”, said Prof. Dr. Satish Rudrappa, Group Director – Aster International Institute of Neurosciences and Spine Care, Aster Whitefield Hospital, Bengaluru.

Microsurgery, constant intraoperative neurological monitoring and precise postoperative care enabled the patient to attain good neurorehabilitation and be up by the very next day. She could even walk back home in less than 10 days from the surgery. Niyati has resumed her life in the U.S with no further complications. Her story is a testament of how cutting-edge technology and medical advancements can transform lives as well as establish India as a leader in the healthcare industry.

World's 1st FDA Approved Bioelectronic Implant for Arthritis

In a groundbreaking move, the U.S. FDA has approved the SetPoint System, the first neuroimmune modulation implant designed to treat moderate to severe rheumatoid arthritis (RA)—especially for patients who haven’t responded well to traditional medications.

What It Is

• A vitamin-sized neurostimulator implanted in the neck via a minimally invasive outpatient procedure.
• Delivers 1-minute daily electrical pulses to the vagus nerve, which helps regulate inflammation and immune response.
• Patients recharge it wirelessly once a week using a collar-like neckband.

Clinical Impact

Based on the RESET-RA trial (242 patients), the device showed:

• Significant improvement in RA symptoms within 3 months.
• Sustained benefits at 12 months.
• 75% of participants were able to stop other RA medications entirely.
• Reported serious adverse events were low (~1.7%).

Why It Matters

• RA affects over 1.5 million Americans, causing chronic pain, joint damage, and disability.
• Traditional treatments like DMARDs and biologics can be costly and lose effectiveness over time.
• This implant offers a non-pharmaceutical, long-term solution—potentially lasting up to 10 years.

Bioelectronic Medicine Milestone

This marks a major leap in bioelectronic medicine, using the body’s own neural circuits to combat disease. SetPoint Medical plans a targeted U.S. rollout in late 2025, with broader availability expected in 2026.

The results of the RESET-RA study, which led to the FDA approval, are published in the journal Bioelectronic Medicine.

UST and ThinkBio.Ai Forge Strategic Alliance to Accelerate AI-Driven Innovation in Biopharma and Healthcare

UST, a leading digital transformation solutions company, has partnered with ThinkBio.Ai®, an AI-powered solutions provider for biopharmaceutical and healthcare organizations. This strategic partnership will empower UST to more efficiently leverage its expertise in digital transformation and advanced solutions to complement ThinkBio.Ai’s innovative AI-powered R&D capabilities. Together, the companies will deliver transformative solutions that accelerate AI transformation journeys and improve outcomes for biopharma and healthcare organizations worldwide.

Leveraging advanced in-house expertise in oncology, immunology, neurology, and cardiology, ThinkBio.Ai has developed a suite of AI-powered solutions to address critical challenges across pharma and biotech preclinical and clinical R&D pipelines. These include data-driven strategies to identify the most optimal treatments, salvaging failed drugs through repurposing or combination therapies, and improving clinical trial success through biomarker-driven patient stratification and digital twin-enabled trial matching.

In addition, ThinkBio.Ai’s AI-enhanced Research Co-pilot (R-COP™) utilizes AI to extend the existing Laboratory Information Management System (LIMS) capabilities. Fully interoperable with existing infrastructure, this next-generation tool transforms routine processes into dynamic, insight-driven research operations. These solutions are designed to support biopharma companies and healthcare providers in accelerating innovation and improving patient care.

ThinkBio.Ai’s biological and clinical insights are powered by experts and delivered through the BioThinkHub™ data platform, drawing from expertly curated data and knowledge from proprietary and public data sources.

“This partnership will bring our unique AI and knowledge-based transformation products and solutions for Research and Discovery (R&D) to UST’s focus on digital transformation capabilities and building Gen AI solutions for different industries, including the life science sector. Together, we will build custom ecosystems to help clients and partners stay ahead in a well-regulated, dynamic, and competitive landscape,” said Pradeep Palazhi, Founder and Chief Executive Officer, ThinkBio.Ai®.

“We will integrate ThinkBio.Ai’s AI-powered R&D transformation solutions with UST’s strengths in digital transformation and Gen AI across life sciences – pharma, biotech, and medical devices. This strategic collaboration will drive innovation, accelerate time-to-value, and deliver measurable impact across the research and development value chain for our customers,” said Anu Koshy, Life Science cluster leader, UST.

NephroPlus Files IPO Papers with SEBI; Asia’s Largest Dialysis Provider Eyes Market Expansion

• Rs. 129.1 crores earmarked towards opening new dialysis clinics
• OFS of 1.27 crore equity shares

Nephrocare Health Services Limited known for its brand NephroPlus, Asia’s largest dialysis services provider and fifth largest globally (in terms of number of treatments performed in Fiscal 2025) (as per a F&S report), has filed the draft red herring prospectus (DRHP) with capital markets regulator SEBI to raise funds through an initial public offering (IPO).

NephroPlus, incorporated in 2009, is the largest organized dialysis service network in India, having 447 clinics across 269 cities in 21 states and 4 Union Territories, and serving more than 33,000 patients globally on an annual basis, and has a revenue market share of over 50% in India’s organized market (in terms of number of treatments). It has also expanded its international footprint to include Philippines (34 clinics), Uzbekistan (4 clinics), Nepal (5 clinics) and has entered the Middle East market through Kingdom of Saudi Arabia recently.

It offers both haemodialysis, with capabilities such as home haemodialysis, hemodiafiltration, holiday dialysis, dialysis on call, and dialysis on wheels, ensuring patients have access to the most suitable and convenient treatment options. As of March 31, 2025, NephroPlus had more than 5,000 dialysis machines and had performed over 3.30 million treatments.

Vikram Vuppala, BVP (Bessemer Venture Partners) Trust, Edoras Investment Holdings Pte. Ltd., Healthcare Parent Limited (HPL), Investcorp Private Equity Fund II (IPEF II) and Investcorp Growth Opportunity Fund (IGOF) are the Promoters of the Company.

According to the DRHP, the proposed IPO of the Hyderabad based company is a combination of a fresh issue of equity shares aggregating up to Rs. 353.4 crores and an offer for sale (OFS) of up to 1,27,92,056 equity shares (1.27 crore equity shares) by the selling shareholders.

As part of the OFS, the Promoter Selling Shareholders include Investcorp Private Equity Fund II, Healthcare Parent Limited, Investcorp Growth Opportunity Fund and Edoras Investment Holdings Pte. Ltd. and Other Selling Shareholders include Investcorp India Private Equity Opportunity Limited, International Finance Corporation, 360 One Special Opportunities Fund - Series 9 and 360 One Special Opportunities Fund - Series 10.

NephroPlus proposes to utilize the Net Proceeds of the Fresh Issue towards capital expenditure to the tune of Rs. 129.1 crores for opening new dialysis clinics in India; Rs 136 crores for pre-payment or scheduled repayment of certain borrowings availed by the company and rest on general corporate purposes.

The company, in consultation with the BRLMs, may consider a Pre-IPO Placement aggregating up to Rs. 70.6 crores; prior to filing of the Red Herring Prospectus with the ROC. If the Pre- IPO Placement is undertaken, then the fresh issue will be reduced to the extent of such Pre-IPO placement.

In FY25, NephroPlus reported revenue from operations of Rs. 755.8 crores and profit after tax of Rs. 67 crores.

Currently, kidney disease is the third fastest-growing cause of death globally and diabetes and hypertension have been recognized as the two leading drivers of chronic kidney disease (CKD). Rapid urbanization and lifestyle changes have further contributed to the increased incidence of CKD.

ICICI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited and Nomura Financial Advisory and Securities (India) Private Limited are the Book Running Lead Managers to the issue.

Over 70% Employees Face Lifestyle-related Health Risks: CII–MediBuddy Report

• Only 20% of employers offer regular health screening

MediBuddy, India’s largest digital healthcare company, in collaboration with CII, today unveiled the second edition of its corporate wellness report, marking a continued effort to decode the evolving landscape of employee well-being in India Inc. The latest edition, titled Workplace Health Reimagined: Corporate India’s Readiness for Digital Health Leadership, highlights how employee wellness is evolving from a peripheral initiative to a strategic lever for workforce productivity, talent retention, and business continuity.

India’s healthcare and workplace wellness landscape is undergoing a significant transformation, with wellness emerging as a national priority in the journey towards Viksit Bharat 2047. This is being shaped by rising medical inflation (14%), increased chronic disease risk, a digitally empowered workforce, and growing demand for inclusive and preventive care models.

In a post-pandemic world, where hybrid work models have become the norm, organisations are rethinking wellness, placing equal weight on physical and mental health, and moving from episodic to always-on care models. Technology is at the heart of this transformation; AI-driven insights, data-enabled personalisation, and mobile-first platforms are enabling more impactful care delivery. The nation's digital health infrastructure demonstrates remarkable scale. Public health initiatives such as the Ayushman Bharat Digital Mission (ABDM) and the IRDAI’s push for 100% cashless insurance claims are further accelerating the shift toward digitally integrated, OPD-first healthcare systems. Together, digital infrastructure and insurance are proving to be critical enablers of equitable, future-ready wellness delivery across India.

The report reveals a stark reality of over 70% of employees carrying at least one lifestyle-related health risk, yet only 20% of employers providing routine health screenings. This alarming scenario calls for a shift from episodic, event-based health programs to always-on, digital-first ecosystems that drive workforce productivity, talent retention, and business continuity, all fostering business growth in today’s evolving times of shifting workforce priorities.

Key findings/highlights from the report:

• Macro View: The National Wellness Landscape
• Rising Burden of NCDs: Non-communicable diseases now account for 63% of all deaths in India, with heart disease, diabetes, and stroke impacting the workforce at median ages of 32, 34, and 36, respectively.
• Healthcare Infrastructure Crisis: The doctor-to-population ratio remains below WHO guidelines, with 70% of Indians in rural/semi-urban areas facing significant access barriers to diagnostics and routine care. 
• Healthcare Coverage Crisis: Only 41% of Indian households have any form of health insurance, leaving over 50 crore people, belonging largely from India’s 40-crore “missing middle” population, particularly comprising gig, daily wage, and informal workers, vulnerable to catastrophic health expenses. 
• Low OPD Insurance Penetration: OPD insurance penetration in India remains below 0.1%, a significant gap compared to over 85% in the US and 95% in Singapore, leaving most outpatient expenses uncovered, despite OPD accounting for nearly 70% of out-of-pocket healthcare spending
• High Out-of-Pocket Spending: OOPE accounts for 63% of India’s total health spend. 

Within Workplaces: The Corporate Lens

• Productivity Loss: Presenteeism and chronic illnesses cost Indian companies up to ₹1.12 lakh per employee annually, while structured wellness programs deliver a 3–4x return on investment
• Limited Access to Diagnostics: Less than 20% of corporate health programs cover essential diagnostics, despite their role in 60–70% of clinical decisions
• Low Preventive Screening for Women: Only 1.9% of eligible Indian women undergo cervical cancer screening, and just 36% of corporates provide targeted wellness benefits for women
• Gaps in Women-Centric Benefits: Just 36% of corporates offer targeted wellness benefits for women, with even fewer extending support for eldercare and mental health. 
• Lifestyle Risks and Screening Gaps: Over 70% of employees have at least one lifestyle-related risk factor, yet only 20% of employers provide routine health screenings. 
• SMEs Lag in Wellness Coverage: Although SMEs employ over 111 million people, only 9% offer structured wellness programs. 
• Corporate Wellness Readiness: India’s average Corporate Wellness Quotient (CWQ) score stands at 55/100, with fewer than 15% of companies achieving a ‘Mature’ wellness readiness level

Satish Kannan, Co-founder & CEO, MediBuddy, said, “India’s journey towards becoming a Viksit Bharat by 2047 cannot rest on economic metrics alone; it must be built on the health, productivity, and well-being of its people. As we stand at this inflection point, employee wellness can no longer be treated as an optional benefit but must be considered a strategic imperative. With rising health risks and evolving workforce expectations, this report in collaboration with CII offers actionable insights and data-driven frameworks to help organisations transition from annual health camps to always-on, digital-first ecosystems. At MediBuddy, we are happy to support this transformation by delivering care that is proactive, personalised, and powered by technology.”

Insights from the report: Trends reshaping care culture

The report highlights how employee wellness in India is moving beyond one-size-fits-all health programs to more integrated, inclusive, personalised, and digitally powered wellness solutions. Employees now expect benefits that reflect their life, role, and risk profile across domains such as mental health, chronic care, eldercare, and preventive screenings. At the same time, employee engagement is being increasingly driven by features such as gamified health journeys and wellness wallets. Additionally, mobile-first platforms and OPD access for dependents are now becoming differentiators in how employees engage with corporate wellness programs, with inclusion-focused benefits becoming key in addressing diverse workforce needs.

To direct this shift, the report introduces the Corporate Wellness Quotient (CWQ), an original and comprehensive benchmarking tool measuring digital wellness maturity and readiness across four pillars: access & affordability, policy integration, digital enablement, and employee engagement; and the ten-step wellness blueprint, which offers companies a strategic roadmap to build resilient and inclusive care ecosystems.

About MediBuddy

MediBuddy has always been at the forefront of India’s digital healthcare transformation. The digital healthcare company has a partner network of 125,000+ doctors across 22+ specialities, 7,500+ hospitals and clinics, 7,700+ diagnostic centres, and 10,000+ pharmacies, along with a team size of 2,300+ members. Serving 100,000+ lives per day, it has created an integrated healthcare ecosystem that offers patients seamless access anytime and anywhere, 24x7, 365 days a year. With its healthcare services available in 16 Indian languages to enable customer-friendly consultation, MediBuddy is bridging the urban-rural quality healthcare divide. MediBuddy offers online and offline doctor consultations, medicine delivery, lab tests at home, mental health consultations, and surgery care, among other healthcare services.

Jaslok Hospital Partners with AnginaX AI to Launch Maharashtra’s First Operational AI-Powered Heart Disease Prevention Model

In a landmark initiative that could redefine how India tackles its leading cause of death, Jaslok Hospital & Research Centre has partnered with AnginaX AI, India’s first licensed AI Doctor Assistant in cardiology, to launch Maharashtra’s first operational AI-powered heart disease prevention model.

This collaboration places Jaslok at the forefront of India’s shift from late-stage cardiac intervention to early, technology-driven prevention. The advanced AnginaX AI system, now deployed across Jaslok’s outpatient departments, enables doctors to assess cardiovascular risk in just seconds using structured, science-backed reports that identify risk even before symptoms appear and recommend personalized lifestyle and treatment plans.

With heart disease affecting millions of Indians and often going undetected until it’s too late, this prevention model brings speed, clarity, and access to the very first point of contact: the OPD.

“For decades, cardiology has focused on damage control.” said Padma Bhushan Awardee Dr. Ashwin B. Mehta, Director of Cardiology at Jaslok Hospital. “But with advanced AI, we can now assess who is at risk before damage begins. This is not just innovation, but reimagining the timeline of care."

The AnginaX system evaluates more than 20 critical clinical and lifestyle-based indicators, including extended lipid profiles, blood sugar, inflammatory biomarkers, metabolic complexities, family history, and lifestyle patterns. Based on validated Indian data, the system generates a structured clinical summary that includes individualized risk stratification, investigation recommendations specific to each patient, and clear, actionable treatment and follow-up guidance.

“The AnginaX AI system gives us clinical clarity in under a minute, especially vital in high-volume OPD settings.” said Dr. Ajit Desai, Senior Cardiologist at Jaslok. “We’re now able to consult more patients, detect silent risks early, and guide people to act before their first symptom.”

Recognizing that cost and fear are often barriers to early checkups, Jaslok and AnginaX have ensured the program is fast, accessible and affordable, making prevention routine rather than rare.

“This isn’t just about digital transformation, but about medical timing,” said Mr. Jitendra Haryan, CEO of Jaslok Hospital. “Our hospital is proud to lead this change in India’s healthcare system. When technology and medicine work together, lives are saved earlier.”

Jaslok also launched AI-powered initiative “Dil Fit, Life Hit” under the leadership of Dr. Ashwin B. Mehta, bringing structured cardiovascular prevention into everyday clinical care. The program empowers doctors, transforms OPD practice, and makes prevention accessible to every patient, not just those with symptoms.

Naman Gosalia, Founder of AnginaX AI, added: “We’ve built an advanced AI medical system that fits seamlessly into any hospital or clinic, helping doctors halt the progression of cardiovascular disease through precision-led risk assessment and personalized treatment recommendations. Our mission is to bring primary prevention to every clinic, every hospital and every corner of India without disrupting how doctors practice.”

“The KPI of this model was simple: could it work on my own mother? We made a clear decision that we would only release it if it worked on her. We tested it on our mother first before going into the pilot. That trial was successful and it gave us the conviction to move forward.” he said.

“Launching it at Jaslok and having their leadership activate it first in Maharashtra, reflects a shared belief that people deserve better outcomes, and prevention should not come with fear, friction, or financial burden. This partnership helps us put the patient first and take this mission to scale across India.”

Dr. Neeraj Desai, Strategic Medical Advisor at AnginaX AI said, “AnginaX AI system is a bridge between data and decision, between missed chances and timely care. In medicine, timing is everything. And for the first time, we are putting timing on the side of prevention”. 

AI-based screening has already begun at Jaslok. Doctors are now taking swift, informed preventive steps, especially for patients who might otherwise remain undiagn

Common Kitchen Herbs Show Promise in Slowing Alzheimer’s Disease

Scientists have discovered that common herbs like rosemary and sage may help slow down Alzheimer’s disease. These herbs have a natural ingredient called carnosic acid. The researchers created a special lab-made version of it, called diAcCA, which activates only in damaged parts of the brain.

This compound was tested on mice that showed signs of Alzheimer’s. The results were encouraging:

• Better memory and learning in mice
• Healthier connections between brain cells
• Less buildup of harmful substances in the brain
• Lower brain swelling (inflammation)

The special thing about diAcCA is that it stays inactive until it finds a problem in the brain, so it doesn’t affect healthy areas.

Cooking with rosemary or sage won’t have the same effect, because the useful compound needs to be specially made and given in a proper form.

What's next for this research:

• More safety testing in animals
• Trials in healthy people to check if it’s safe
• Bigger trials in Alzheimer’s patients to see if it truly works
• Getting government approval if the results are positive
• Possibly combining with other Alzheimer’s drugs

This study is an exciting step, but more research is needed before it becomes a medicine for people.

Before moving to humans, researchers will continue testing the stabilized compound diAcCA in animals to confirm it’s safe at different doses over time.

Phase 1 human clinical trials – If animal studies go well, the next step is small-scale trials in healthy volunteers to test safety, dosage, and how the body processes the drug.

If the trials show strong results, the compound could be submitted for approval by agencies like the FDA.

Researchers may also test diAcCA alongside existing Alzheimer’s drugs to see if it enhances their effects or reduces side effects.

The fact that carnosic acid is already on the FDA’s “generally regarded as safe” list could help speed things up, but human trials are still essential to prove it works and is safe in real-world conditions.

India’s COVID-19 Resurgence: What the Numbers Reveal and Why Vigilance Matters

India is witnessing a fresh uptick in COVID-19 cases, with 257 active infections reported across nine states as of May 19, 2025. While the numbers remain relatively low compared to previous waves, health experts urge caution, particularly as new Omicron subvariants— JN.1 and its descendants LF.7 and NB.1.8 —drive infections

Where Are Cases Rising?

The states reporting the highest increases include:

• Kerala: 95 cases (sharpest rise)
• Maharashtra: 56 cases
• Tamil Nadu: 66 cases
• Delhi, Gujarat, Haryana, Karnataka, Rajasthan, Sikkim: Smaller clusters.

Despite the rise, experts emphasize that no new variant of concern has emerged, and hospitalizations remain low. However, the actual number of infections may be higher than reported, as many individuals with mild symptoms are not getting tested.

Why Are Cases Rising Again?

Several factors contribute to the resurgence:

• Waning immunity: Many people have not received booster doses.
• Relaxed preventive behavior: Mask-wearing and social distancing have declined.
• Seasonal effects: Increased travel and gatherings may be fueling transmission.
• Global trends: Countries like Singapore and Hong Kong have seen spikes due to Omicron subvariants.

What Symptoms Should You Watch For?

The dominant JN.1 subvariant typically causes mild symptoms, including:

• Fever
• Sore throat
• Cough
• Fatigue
• Runny nose
• Occasional shortness of breath (in vulnerable individuals).

What Can You Do?

Health officials recommend:

1. Wearing masks in crowded places and enclosed spaces.
2. Avoiding unnecessary travel if symptomatic.
3. Getting tested promptly if symptoms appear.
4. Following hand hygiene and respiratory etiquette.
5. Staying up to date with vaccinations and booster doses.

The Bigger Picture: Lessons from the Pandemic

While India’s current COVID-19 situation is not alarming, it serves as a reminder that pandemic preparedness must remain a priority. The rise in cases highlights the importance of genomic surveillance, public health infrastructure, and community awareness in managing future outbreaks.

As the world moves beyond the peak of the pandemic, vigilance—not panic—is key. Staying informed and adopting basic preventive measures can help curb the spread and protect vulnerable populations.

Anaemia Rates in Urban Workforce Fall to 12.14%: MediBuddy Study Highlights Impact of Screenings and Preventive Care

MediBuddy, India’s largest digital healthcare company, has released new research data revealing a significant drop in Anaemia among urban working women—driven by better preventive care, timely screenings, and improved nutrition awareness.

The study, which analysed health records from 4,397 urban corporate employees, found that 32.67% of women surveyed were anaemic—a significant reduction compared to the national urban average of 56.5% reported by National Family Health Survey-5 (NFHS-5, 2019–21) for women aged 15–49. Among male employees, our research shows anaemia prevalence was just 5.63%, and NFHS-5 data also shows the urban average is lower of 25% for men in the same age group.

This improvement is attributed to factors such as rising health literacy, regular screenings, timely interventions, and expanded access to corporate wellness programs promoting balanced diets.

According to the study, working women aged 40–50 emerged as the most vulnerable group, making up 26.44% of all anaemic female respondents, likely due to age-related hormonal changes and higher nutritional needs. Among men, the 40–50 age group also reported the highest incidence (4.40%), suggesting age-related lifestyle and dietary factors may influence anaemia risk for both genders.

On a state-wise level, Maharashtra recorded the highest number of anaemic employees (3.66% of the total sample), followed by Karnataka, Tamil Nadu, and West Bengal. However, several states, including Kerala, Madhya Pradesh, and Gujarat, demonstrated relatively low anaemia prevalence—highlighting regional disparities and the influence of local healthcare programs and outreach efforts.

Despite regional and gender gaps, the overall data suggests a positive trajectory in urban employee health in terms of anaemia.

MediBuddy study shows that anaemia prevalence among urban employees has dropped to just 12.14% over the last five years—a significant improvement compared to the 40%+ national average reported in NFHS-5 (2019–21). This decline reinforces the positive impact of improved health literacy and early interventions, especially through regular health check-ups, across the urban workforce.

Dr. Gowri Kulkarni, Head of Medical Operations, MediBuddy, highlighting the importance of early action, said, "The reduction in anaemia prevalence among urban women is an encouraging indicator that corporate India is waking up to the importance of preventive healthcare. Increased access to regular health check-ups, workplace nutrition initiatives, and timely diagnosis has allowed many women to better manage and reverse nutrient deficiencies. However, continued efforts are needed to bridge the gap completely—especially for those in the most vulnerable age groups."

MediBuddy’s findings reinforce the need for continued investment in preventive health through routine blood tests, iron supplementation programs, and dietary consultations.

Hillchol®: Bharat Biotech’s Oral Cholera Vaccine Demonstrates Success in Phase III Clinical Studies

Bharat Biotech’s Oral Cholera Vaccine Hillchol® has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.

The above study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomized phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol® in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India. In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomized in a 3:1 ratio to receive either Hillchol® or a comparator vaccine.

The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety.

Key highlights from the findings:

• Robust Immunogenicity: Hillchol® demonstrated a greater than 4-fold rise in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, proving non-inferiority to licensed vaccines.
• Strong Safety Profile: Adverse events were mild and comparable between the two vaccines. Broad Age Coverage: The vaccine was well-tolerated and immunogenic across all age groups—including infants (≥1 year), children, and adults.

"This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,” said Dr. Krishna Ella, Executive Chairman of Bharat Biotech.

Dr. Ella added, “Cholera is a vaccine-preventable disease that has faced a surge in outbreaks along with a huge shortage of vaccines. The new generation Oral Cholera Vaccine Hillchol®, featuring a simplified single stable O1 Hikojima strain, inducing robust antibodies against both Ogawa and Inaba serotypes, aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.”

Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Studies have estimated that 2.86 million cases and 95,000 deaths occur annually.

HillChol® Pack

With Hillchol®, Bharat Biotech strengthens its commitment to combating global infectious diseases through innovation and clinical excellence. As cholera continues to threaten communities lacking clean water and sanitation, Hillchol® provides a streamlined, scalable solution designed to support global health programs and ensure equitable access to life-saving vaccines.

Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol®.

Published in the ScienceDirect, Vaccine journal: https://www.sciencedirect.com/science/article/pii/S0264410X25002956?via%3Dihub

About Bharat Biotech:

Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 19 vaccines, 4 biotherapeutics, registrations in more than 125 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. Having delivered more than 9 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC®), Rabies, Chikungunya, Zika, Cholera, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.

Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, ROTAVAC 5D®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. HILLCHOL®, an oral vaccine against cholera, was launched in 2024. The acquisition of Chiron Behring Vaccines has positioned Bharat Biotech as the world's largest rabies vaccine manufacturer with Chirorab® and Indirab®. To learn more about Bharat Biotech, visit www.bharatbiotech.com.

Boosting Medicinal Plant Farming: Govt & Industry Join Hands to Help Farmers

A recent Stakeholder Consultation in New Delhi focused on boosting India's medicinal plant sector through collaboration, regional clusters, and industry partnerships. Officials emphasized the need for policy support, dedicated markets, and financial incentives to empower farmers and foster sector growth.

Key discussions included:

• Mission-mode program for medicinal plant cultivation, identifying best practices and efficient techniques.
• Industry-farmer partnerships to ensure stable markets and fair pricing.
• Region-specific clusters for medicinal plants to streamline production and marketing.
• Expansion of AYUSH sector, which has grown eightfold in the past decade, highlighting export potential.

The consultation underscored the economic opportunities in medicinal plant cultivation, particularly in light of rising global demand for natural and holistic healthcare products.

In his opening remarks, Shri. Devesh Chaturvedi, Secretary, Ministry of Agriculture & Farmers Welfare, highlighted that there is a scope to increase domestic production of medicinal plants as inter-state trade and export of medicinal plants. He highlighted the need for better convergence between Ministry of AYUSH and Agriculture departments and collaboration with State Medicinal Plant Boards, to promote medicinal plants at national level. He also mentioned that important medicinal plants have been included under the Mission for Integrated Development of Horticulture (MIDH) scheme, DA&FW. He stressed that there is a need for a mission-mode program for medicinal plant cultivation, identifying good practices of cultivation, efficient techniques, etc., which will help in the upliftment of the sector.

Shri Vaidya Rajesh Kotecha, Secretary, Ministry of AYUSH highlighted that there is a huge possibility of growth in the sector. The AYUSH manufacturing sector has grown by 8 times in the last 10 years and has vast export potential. The sector has enormous economic opportunities, and especially after the COVID-19 pandemic, the demand for AYUSH products including medicinal plants has grown immensely.

66% HealthTech Leaders Say Their Organizations Generating Business Value From Several Ai Use Cases :KPMG Report

KPMG has unveiled a new report titled “KPMG Global Tech Report: Healthcare Insights” to better understand how healthcare organizations are navigating the complexities of digital transformation, targeting their technology investments, and deriving value.

By examining the perspectives of 122 healthcare technology leaders from around the world (based on a comprehensive survey of 2,450 global technology leaders including chief digital officers, CIOs, CTOs, CISOs, chief AI officers and other executives) the report provides valuable insights into how healthcare systems and organizations are on the precipice of a technology revolution, and are leveraging advanced technologies and tools to streamline operations, reduce costs and, above all, enhance patient experiences.

“Today healthcare technology leaders believe robust regulatory frameworks are a must to ensure the safety and privacy of data in cloud-hosted solutions. They believe this assurance enables them to advance technological innovation with confidence. Prioritizing comprehensive data interoperability frameworks is critical for seamless communication between systems across organizations and jurisdictions. Such connectivity can drive accurate patient care, promote global collaboration in medical research, and strengthen AI model training through access to diverse datasets.” said Lalit Mistry Partner and Co-head, Healthcare Sector, KPMG in India.

Key Findings from the Report:

• 70 per cent of healthcare respondents are satisfied with the amount of value they are getting from their technology investments.
• Compared with a year ago, more healthcare organizations are developing and testing data and analytics strategies or already have a strategic vision for their capabilities
• 70 per cent say cyber security teams are typically involved in the earliest planning stages and have a high degree of influence when it comes to tech investment decision-making
• 66 per cent of healthcare technology leaders say their organizations are generating business value from several AI use cases
• 61 per cent of healthcare technology leaders are currently prioritising AI and Automation as they consider how to invest in technology to support their ambitions.
• 57 per cent admit that flaws in their organizations’ enterprise IT systems disrupt business as usual on a weekly basis.
• Top 3 factors slowing down digital transformation in healthcare includes – Cyber security and privacy concerns, transformation fatigue and immature data management strategies. 
• Healthcare leads all other sectors when it comes to prioritizing and investing in Web3 technology including blockchain and tokenization.

AIIMS Jammu and 4baseCare Launches Centre for Advanced Genomics & Precision Medicine

The All India Institute of Medical Sciences (AIIMS) Jammu has officially initiated laboratory operations with the illumina NextSeq 2000 sequencing machine, at its newly established Centre for Advanced Genomics & Precision Medicine — marking a transformative step toward making affordable, precision-driven cancer care accessible to patients across India.

Inaugurating the state-of-the-art facility were key dignitaries, including Prof. (Dr) Shakti Kumar Gupta, Executive Director and CEO of AIIMS Jammu; Lt Gen Dr Sunil Kant, Dean Research and Medical Superintendent; Prof. Dr Meeta Gupta, Dean (Academics); Prof. Dr Shabab L Angurana, Associate Dean (Research); Mr. Shailender Slathia, Registrar; Dr. Poonam Sharma, Head, Department of Pathology; and Dr. Sudharshan, Vice President – Global Operations at 4baseCare.

Prof (Dr) Shakti Kumar Gupta, Executive Director and CEO, AIIMS Jammu, stated, “For every patient we treat, we are treating a mother, a father, a sister, or a brother. This partnership is our promise to every family who walks through our doors that we will do everything in our power to bring them the care they deserve.”

The Centre, developed in collaboration with 4baseCare, is equipped with advanced Next Generation Sequencing (NGS) technology, offering comprehensive genomic profiling for cancer patients. This powerful capability enables clinicians to design highly personalized, targeted treatment plans tailored to each patient’s unique molecular profile.

“By integrating cutting-edge genomic data with AI-powered diagnostics, the Centre is poised to significantly improve early disease detection, refine therapy choices, and minimize ineffective treatments — ultimately enhancing both patient outcomes and quality of life,” said Dr. Sudharshan Elangovan , Vice President – Global Operations at 4baseCare.

Traditionally, access to such advanced genomic testing has been prohibitively expensive for many patients. However, with this initiative, high-quality NGS-based tests will now be made available at affordable costs, paving the way for greater inclusivity in precision oncology across India.

Further solidifying its role as a national referral hub, the Centre will accept samples from patients and healthcare providers across the country, ensuring that cutting-edge molecular diagnostics are accessible, regardless of geographical barriers.

For more details, visit, https://4basecare.com/